Condition: Non-small Cell Lung Cancer Stage IIIB/IV · Head and Neck Squamous Cell Carcinoma (HNSCC) · Colorectal Adenocarcinoma · Sponsor: Akeso
This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.
This description comes directly from the study's public registry record.
Wenting Li,M.D. · +86(0760)89873999 · clinicaltrials@akesobio.com
Hongxu Liu,M.D. · Hongxuliu@qq.com
Always discuss trial participation with your own doctor first.
| Liaoning Cancer Hospital | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06943820